

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Baricitinib for severe alopecia areata

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when a DG issued)

- | | |
|----|---|
| 1. | Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
|----|---|

During DG consultation, the following additional issues were raised:
--

- | |
|---|
| <ul style="list-style-type: none">• Severe AA is associated with 'severe physical disfigurement' which is classed as a disability by UK Disability and Equality Act 2010• Viewpoint for males and young people are lacking |
|---|

- | | |
|----|---|
| 2. | If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|----|---|

Not relevant.

- | | |
|----|--|
| 3. | If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
|----|--|

Not relevant.

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not relevant.	

5.	Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes, section 3.17	

Approved by Associate Director (name):Janet Robertson.....

Date: 02 May 2023